Introduction {#S1}
============

Penile duplex ultrasound (PDU), combined with pharmacologic stimulation of erection, is the gold standard approach for evaluation of multiple penile conditions. These include erectile dysfunction (ED), Peyronie's disease (PD), penile fracture, and trauma^1^. Unlike other imaging modalities (CT or MRI), ultrasound is frequently performed by urologists rather than radiologists. In addition to a vascular and anatomical evaluation, PDU also provides a dynamic, quantifiable, consistent, and reliable method for evaluation of several structural conditions. It can help detect fibrotic plaques and calcifications characteristic of PD, defects in the tunica albuginea and variable echogenicity in the corpus cavernosa in the setting of trauma or features of priapism that differentiate between high and low flow priapism, including arteriocavernosal fistulas and high-resistance cavernosal arterial flow. Anatomic variations in vasculature can also be detected.

Since Lue et al.'s early description of penile ultrasound in 1985, technological improvements in imaging have significantly improved its utility and precision ([@R1]). After an intracavernosal injection of a vasoactive agent, a 7.5- to 12-MHz linear array ultrasound probe is used to scan the penis typically on the ventral surface at a fixed angle ([@R2]). It is recommended that the angle between the incident beam and the vector of blood flow i.e. the angle of insonation be maintained at 60° or less ([@R3], [@R4]). The peak systolic velocity (PSV), end diastolic velocity (EDV), and a calculated resistive index (RI=\[PSV-EDV\]/PSV)) are measured to assess penile hemodynamics. Change in diameter of the cavernosal artery and flow in the deep dorsal vein may also be measured. A PSV lower than 25 cm/second or an EDV greater \> 5 cm/second in the setting of adequate arterial flow have been the major criteria used to define and distinguish ED due to arterial insufficiency or corporal veno-occlusive dysfunction, respectively ([@R1], [@R2], [@R5]--[@R8]).

A lack of standard approaches to performing and interpreting PDU limits its utility. In 2011, the American Institute of Ultrasound in Medicine (AIUM) and the American Urological Association (AUA) developed guidelines for penile ultrasound technique and training for physicians who evaluate and interpret urologic ultrasound examinations ([@R9]). Recognizing the variability and need for standardization, standard operating procedures to emphasize guidelines for PDU have been published in an attempt to emphasize correct technique ([@R2], [@R10]). To assess adoption of and adherence to the above-mentioned protocols and guidelines, we examined the variability in international practice patterns, technique and interpretation among practitioners who perform PDU. Further standardization will help improve our ability to diagnose penile pathology and promote more effective comparison of results and clinical research in the field.

Materials and Methods {#S2}
=====================

A 30-question electronic survey was developed to assess anonymous demographic information, current PDU practice patterns, technique and interpretation. We placed an emphasis on who performs the PDU, intracavernosal injection protocols, and which parameters are measured during the study. The entire content of the survey is available as [Supplementary information](#SD1){ref-type="supplementary-material"}. This survey was then distributed to all 1,996 members of the International Society for Sexual Medicine (ISSM) using Survey Monkey (SurveyMonkey Inc, San Mateo, CA, USA). All participants provided anonymous consent prior to starting the survey, and the study and survey were approved the by the Baylor College of Medicine institutional review board. The survey was kept open for one month and only completed surveys were used for analyses. Descriptive analyses were performed, and chi-square test was used to determine association between categorical variables. All statistical analyses were done using SPSS v22 (IBM, NY).

Results {#S3}
=======

Approximately 9.5% (190) of all 1,996 current ISSM members completed the survey. The majority (65%) of respondents were fellowship-trained in Andrology, Sexual Medicine, or Male Infertility. 94% of respondents were males and 59% were in private practice. Almost 80% of respondents surveyed reported using PDU, with more North American practitioners utilizing PDU than their European counterparts (94% vs. 69%, p \< 0.01). Over 1/3 of practitioners using PDU perform more than 10 studies per month, and 69% are done in a urology clinic. Approximately 62% of PDU studies were performed by a urologist and 77% were interpreted by a urologist. Demographic details are presented in [Tables 1](#T1){ref-type="table"},[2](#T2){ref-type="table"}, and [3](#T3){ref-type="table"}. Most of the respondents listed ED (90%) and PD (74%) as indications for PDU. All other indications reported are presented in [Table 4](#T4){ref-type="table"}.

Although almost 90% of practitioners reported using a standardized protocol, only 35% of practitioners were aware of the AIUM/AUA guidelines. Over 10 different intracavernosal pharmacologic mixtures were used to initiate erections prior to PDU ([Table 5](#T5){ref-type="table"}), with 10 mcg of Prostaglandin E1 being the most commonly used. 17% of respondents did not repeat dosing for insufficient erection and 34% reported never using pharmacologic intervention to facilitate detumescence following PDU. No form of audio-visual sexual stimulation was used by approximately 35% of respondents.

Overall, 60% of respondents assessed cavernosal artery flow at the proximal penile shaft and 56% of respondents assessed flow with the ultrasound probe angled at 60 degrees or less relative to the penis. Urologists personally performing PDU were almost twice as likely to assess cavernosal arterial flow with the probe at the proximal penile shaft (73% vs 40%, p\<0.01) and at a 60-degree angle or less (68% vs 36%, p\<0.01) compared to non-urologists. These differences in technique are presented in [Table 6](#T6){ref-type="table"}. The timing and frequency of cavernosal artery flow measurements after response to ICI was highly variable amongst respondents ([Table 5](#T5){ref-type="table"}). Large differences in PDU diagnostic thresholds were reported ([Table 5](#T5){ref-type="table"}), with 38% of respondents defining arterial insufficiency with a PSV \< 25 cm/sec, and 53% of respondents defining venous occlusive disease with an EDV \> 5 cm/sec. Urologists interpreting PDU were more likely to define venous occlusive disease as EDV \> 5 cm/sec (63% vs 34%, p \< 0.01) than non-urologists ([Table 6](#T6){ref-type="table"}). No similar association was observed for arterial insufficiency, with the most common definition of PSV being \< 25 cm/sec. No associations were found based on training or region.

Discussion {#S4}
==========

To our knowledge this is the first survey to evaluate variability in practice patterns, technique, and interpretations among practitioners using PDU for evaluation of erectile function. More North American practitioners use PDU than Europeans (94% vs 69%, p\<0.01), which may be due to geographic differences in management, reimbursement, or availability. According to AUA guidelines, intracavernosal injection with or without PDU is indicated prior to any invasive intervention for PD. EAU guidelines recommend PDU only in the context of questionable erectile function to ascertain vascular parameters, but not for measurement of plaque size in everyday clinical practice([@R11], [@R12]). However, although PDU is explicitly mentioned as a specialized diagnostic test for vascular investigation for ED in EAU guidelines, AUA guidelines state that "additional testing such as testosterone level measurement, vascular and/or neurological assessment, and monitoring of nocturnal erections may be indicated in select patients"([@R12], [@R13]). Reimbursement may favor North Americans due to varying healthcare models but no differences were observed in PDU use according to practice type (academic practice vs private practice) in our cohort.

A significant number of PDU examinations were performed and interpreted by non-urologists, including radiologists, ultrasound technicians, and advanced practice providers (Physician's Assistant/Nurse Practitioners). Given the operator-dependent nature of PDU, Aversa and Sarteschi had previously suggested that practitioners perform a minimum of 200 investigations per year to be considered well trained ([@R4]). The guidelines developed by the AIUM in collaboration with AUA also detail the required number of yearly volume requirements and course credits depending on a physician's background to be considered competent. This document favors a minimum of 100 diagnostic genitourinary ultrasound examinations to gain experience and proficiency with sonography as a diagnostic modality and 50 diagnostic genitourinary ultrasound examinations a year for a physician to maintain skill ([@R14]). According to our survey, 33% of respondents would fall below this benchmark set by the AUA/AIUM to maintain expertise using this modality.

Psychological and environmental factors influence erectile function and in turn PDU interpretation. The selection of vasoactive pharmacological substances used to achieve an erection is highly variable. A significant number of patients who are not sufficiently dosed or stimulated to achieve maximal rigidity may be undergoing suboptimal ultrasound procedures which do not result in an accurate diagnosis. Patients should be involved during this procedure to evaluate erection quality, especially since a large number of patients exhibit needle phobia ([@R15]--[@R17]). In addition, re-dosing, and the use of audio-visual sexual stimulation might be required in the setting of inadequate response compared to erections at home.

The principal source of error in flow velocity determination is an incorrectly used Doppler angle([@R8]). Distal locations and larger probe angles artificially lower PSV measurements and may lead to incorrect arterial insufficiency diagnoses([@R18]--[@R20]). The standardization and knowledge of vascular parameters necessary for diagnosis is a vital area for improvement. Urologists should be aware of the standard pattern of Doppler waveform progression associated with hemodynamic changes in corporal pressure during progression to normal full erection. Measurements should be interpreted in conjunction with erectile response to avoid false positives associated with PDU measurements.([@R6], [@R21]) For example, EDV may initially increase in the response phase prior to decreasing as rigidity and veno-occlusion are achieved and PSV decreases following full penile rigidity. The presence of significant sympathetic tone in young, anxious patients may falsely lower PSV and increase EDV, further complicating the process.([@R22]--[@R24]) The diagnosis of mixed or veno-occlusive ED is difficult to make in patients with arterial insufficiency([@R25]--[@R28]). Resistive Index offers another, more specific measure of veno-occlusive disease accounting for PSV but further investigation into its use is needed ([@R29]). The time to full erectile response is variable among patients, contributing to increased likelihood of test misinterpretation. Due to factors including environment, injection protocols, drug used, baseline function, and pathology, several authors have stressed using serial measurements to definitively establish a diagnosis ([@R2], [@R21], [@R30]--[@R32]). The wide variation seen in timing of initial measurement and lack of repeat measurements by a significant number of respondents are concerning for a high prevalence of inadequate PDU studies. This disparity seen in technique and interpretation strongly suggests the need for education and standardization of the approach to and interpretation of PDU.

This study has several limitations that should be discussed. As in any other survey study, recall bias is an inherent limitation. The survey was limited to members of the ISSM and our response rate was only 9.5%. Our results are thus applicable only to providers specifically interested in sexual medicine, and even more specifically, who are interested in membership in an academic society. Our study design neglects the remainder of providers who may be performing PDUs. However, the study provides valuable insight into PDU practice patterns, particularly in light of more recent efforts at standardization of the procedure and interpretation of results.

Conclusions {#S5}
===========

The minimally invasive nature of a PDU, its relatively low cost, and the ability to objectively and effectively diagnose a number of penile conditions make it an essential primary diagnostic modality. Although most respondents report utilizing a standardized PDU protocol, widespread variation exists among practitioners in terms of both technique and interpretation. This variation limits the utility of PDU and may impair accurate diagnosis and appropriate treatment of penile conditions. Our study demonstrates that gaps in knowledge remain, and there is room for improvement in the utilization of PDU. Further standardization and implementation of established protocols could improve patient care and research in the future.
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###### 

Respondent Demographics

  Question                          Responses, n (%)
  --------------------------------- ------------------
  **Gender**                        
      Male                          176 (93%)
      Female                        14 (7%)
                                    
  **Years in Practice**             
      \< 10 years                   64 (34%)
      10 -- 20 years                46 (24%)
      \> 20 years                   80 (42%)
                                    
  **Level of Training**             
      Attending / Board-Certified   166 (87%)
      Resident / Fellow             13 (7%)
      Advanced Practice Provider    11 (6%)
                                    
  **Fellowship training**           
      Yes                           123 (65%)
      No                            67 (35%)
                                    
  **Practice Type**                 
      Private                       112 (59%)
      Academic                      57 (30%)
      Government                    21 (11%)
                                    
  **Region**                        
      North America                 66 (35%)
      Europe                        54 (28%)
      Other                         70 (37%)

###### 

Associations between Demographics and PDU Use

                      Use PDU, n (%)   Do Not Use PDU, n (%)   p Value
  ------------------- ---------------- ----------------------- ---------
  **Respondents**     151 (79%)        39 (21%)                
                                                               
  **Fellowship**                                               
      Yes             102 (83%)        21 (17%)                0.11
      No              49 (73%)         18 (27%)                
                                                               
  **Practice Type**                                            
      Private         84 (75%)         28 (25%)                0.07
      Other           67 (86%)         11 (14%)                
                                                               
  **Region**                                                   
      North America   62 (94%)         4 (6%)                  \< 0.01
      Europe          37 (69%)         17 (31%)                
      Other           52 (74%)         18 (26%)                

###### 

PDU Practice Patterns

  Question                         Responses, n (%)
  -------------------------------- ------------------
  **How frequently?**              
      \> 10 PDUs / month           59 (39%)
      5 -- 10 PDUs / month         42 (28%)
      1 -- 4 PDUs / month          50 (33%)
                                   
  **Where are PDUs performed?**    
      In Urology Clinic            104 (69%)
      In Radiology Department      38 (25%)
      Other                        9 (6%)
                                   
  **Who performs PDUs?**           
      Urologist                    93 (62%)
      Radiologist                  32 (21%)
      Ultrasound Technician        20 (13%)
      Advanced Practice Provider   6 (4%)
                                   
  **Who interprets PDUs?**         
      Urologist                    116 (77%)
      Radiologist                  31 (20%)
      Advanced Practice Provider   4 (3%)

###### 

Indications for PDU

  Question                                  Responses, n (%)
  ----------------------------------------- ------------------
  **Indications for PDU?**                  
    Erectile dysfunction                    171 (90%)
    Peyronie's disease / penile curvature   140 (74%)
    Priapism                                100 (53%)
    Penile trauma                           97 (51%)
    Dorsal vein thrombosis                  63 (33%)
    Abnormality on physical exam            55 (29%)
    Urethral stricture                      19 (10%)

###### 

Technique and Interpretation of PDU

  Question                                                                                                                                                                                                                     Responses, n (%)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  **Standardized PDU protocol?**                                                                                                                                                                                               
    Yes                                                                                                                                                                                                                        134 (89%)
    No                                                                                                                                                                                                                         10 (7%)
    Unsure                                                                                                                                                                                                                     7 (4%)
                                                                                                                                                                                                                               
  **Initial intracavernosal agent?**                                                                                                                                                                                           
    Prostaglandin E1 10 mcg                                                                                                                                                                                                    46 (30%)
    Prostaglandin E1 20 mcg                                                                                                                                                                                                    30 (20%)
    Papaverine 3 mg / Phentolamine 0.1 mg (Bimix 0.1 ml)                                                                                                                                                                       5 (3%)
    Papaverine 6 mg / Phentolamine 0.2 mg (Bimix 0.2 ml)                                                                                                                                                                       3 (2%)
    Papaverine 3 mg / Phentolamine 0.1 mg / PGE1 1 mcg (Trimix 0.1 ml)                                                                                                                                                         25 (17%)
    Papaverine 6 mg / Phentolamine 0.2 mg / PGE1 2 mcg (Trimix 0.2 ml)                                                                                                                                                         9 (6%)
    Variable                                                                                                                                                                                                                   11 (7%)
    Other                                                                                                                                                                                                                      17 (12%)
    Unsure                                                                                                                                                                                                                     5 (3%)
    None                                                                                                                                                                                                                       0 (0%)
                                                                                                                                                                                                                               
  **Additional agent following insufficient erection?**                                                                                                                                                                        
    Yes                                                                                                                                                                                                                        114 (76%)
    No                                                                                                                                                                                                                         26 (17%)
    Unsure                                                                                                                                                                                                                     11 (7%)
                                                                                                                                                                                                                               
  **Frequency of pharmacologic intervention for detumescence?**                                                                                                                                                                
    Never                                                                                                                                                                                                                      51 (34%)
    Around 25% of studies                                                                                                                                                                                                      72 (48%)
    Around 50% of studies                                                                                                                                                                                                      10 (7%)
    Around 75% of studies                                                                                                                                                                                                      7 (4%)
    Always                                                                                                                                                                                                                     4 (2%)
    Unsure                                                                                                                                                                                                                     7 (4%)
                                                                                                                                                                                                                               
  **Where is cavernosal artery flow assessed?**                                                                                                                                                                                
    Perineum                                                                                                                                                                                                                   6 (4%)
    Proximal penile shaft                                                                                                                                                                                                      91 (60%)
    Mid penile shaft                                                                                                                                                                                                           36 (24%)
    Distal penile shaft                                                                                                                                                                                                        1 (1%)
    Unsure                                                                                                                                                                                                                     17 (12%)
                                                                                                                                                                                                                               
  **At what angle is the probe held relative to penis to assess flow?**                                                                                                                                                        
    30 degrees                                                                                                                                                                                                                 19 (13%)
    45 degrees                                                                                                                                                                                                                 35 (23%)
    60 degrees                                                                                                                                                                                                                 30 (20%)
    75 degrees                                                                                                                                                                                                                 3 (2%)
    90 degrees                                                                                                                                                                                                                 30 (20%)
    Unsure                                                                                                                                                                                                                     34 (22%)
                                                                                                                                                                                                                               
  **When is cavernosal artery first assessed after initial response to cavernosal injection?**                                                                                                                                 
    Immediately after erection is obtained                                                                                                                                                                                     39 (25.83%)
    5 minutes after erection is obtained                                                                                                                                                                                       59 (39.07%)
    10 minutes after erection is obtained                                                                                                                                                                                      23 (15.23%)
    15 minutes after erection is obtained                                                                                                                                                                                      4 (2.65%)
    I do not know                                                                                                                                                                                                              9 (5.96%)
    Other                                                                                                                                                                                                                      17 (11.26%)
                                                                                                                                                                                                                               
  **In addition to a baseline assessment and an assessment following initial response to cavernosal injection, how many additional assessments of cavernosal artery flow are completed before the conclusion of the study?**   
    None                                                                                                                                                                                                                       26 (17.22%)
    1                                                                                                                                                                                                                          36 (23.84%)
    \>1                                                                                                                                                                                                                        78 (51.66%)
    I do not know                                                                                                                                                                                                              11 (7.28%)
                                                                                                                                                                                                                               
  **Peak systolic cavernosal artery flow defining arterial insufficiency?**                                                                                                                                                    
    \< 40 cm / sec                                                                                                                                                                                                             1 (1%)
    \< 35 cm / sec                                                                                                                                                                                                             30 (16%)
    \< 30 cm / sec                                                                                                                                                                                                             51 (27%)
    \< 25 cm / sec                                                                                                                                                                                                             73 (38%)
    \< 20 cm / sec                                                                                                                                                                                                             21 (11%)
    Unsure                                                                                                                                                                                                                     14 (7%)
                                                                                                                                                                                                                               
  **End diastolic cavernosal artery flow defining venous occlusive disease?**                                                                                                                                                  
    \> 10 cm / sec                                                                                                                                                                                                             17 (9%)
    \> 7 cm / sec                                                                                                                                                                                                              13 (7%)
    \> 5 cm / sec                                                                                                                                                                                                              101 (53%)
    \> 3 cm / sec                                                                                                                                                                                                              21 (11%)
    \> 0 cm / sec                                                                                                                                                                                                              8 (4%)
    Unsure                                                                                                                                                                                                                     30 (16%)

###### 

PDU Technique by Practitioner Type

                                 Performed by urologist, n (%)   Performed by non-urologist, n (%)   p Value
  ------------------------------ ------------------------------- ----------------------------------- ---------
  **Probe location**                                                                                 
    **Proximal penile shaft**    68 (73%)                        23 (40%)                            \< 0.01
    **Other**                    25 (27%)                        35 (60%)                            
                                                                                                     
  **Probe angle**                                                                                    
    **60 degrees or fewer**      63 (68%)                        21 (36%)                            \< 0.01
    **Other**                    30 (32%)                        37 (64%)                            
                                                                                                     
  **Arterial insufficiency**                                                                         
    **PSV \< 25 cm / sec**       42 (36%)                        14 (40%)                            0.68
    **Other**                    74 (64%)                        21 (60%)                            
                                                                                                     
  **Venous occlusive disease**                                                                       
    **EDV \> 5 cm / sec**        73 (63%)                        12 (34%)                            \< 0.01
    **Other**                    43 (37%)                        23 (66%)                            
